J
Jole Ventriglia
H指数:18
被引数:893
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network
真实世界分析:接受帕博利珠单抗联合阿昔替尼治疗的转移性肾细胞癌患者——坎帕尼亚肿瘤网络证据
Current Oncology
IF3.4
KELIM score: A marker of chemosensitivity in ovarian cancer
KELIM评分:卵巢癌化疗敏感性的标志物
Cancer Treatment Reviews
IF10.5
Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study; a retrospective analysis of italian MITO centers
从末次化疗到死亡的时间在卵巢癌患者中的研究:TO CARE/MITO 42研究;一项意大利MITO中心的回顾性分析
The emerging role of PARP inhibitors in prostate cancer: A narrative review
PARP抑制剂在前列腺癌中的新兴作用:一篇叙述性综述
Cancer Treatment Reviews
IF10.5
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial
奥拉帕利作为铂类耐药性生殖细胞肿瘤的挽救治疗:IGG-02期II临床试验
ESMO OPEN
IF8.3
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
根据BRCA结构域突变和突变类型,PARP抑制剂在晚期高级别浆液性卵巢癌中的疗效
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
卵巢癌中的trabe tedin: 现在是护理标准吗?
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
卵巢癌,子宫内膜癌和宫颈癌的免疫治疗: 最新技术和未来展望
CANCER TREATMENT REVIEWS
IF10.5

